Mucin 1 and survivin peptide–major histocompatibility complexes (MUC1/Survivin-pMHC)

Mucin 1 (MUC1) and survivin (BIRC5) are prominent tumor-associated antigens (TAAs) that are processed into peptides and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules (Source: UniProt P15941, O15392). MUC1 is a transmembrane glycoprotein that is overexpressed and aberrantly glycosylated in over 90% of breast cancers and many other solid tumors, where it promotes cell signaling and survival (Source: PMID: 22235228). Survivin is a member of the inhibitor of apoptosis (IAP) family that is highly expressed during fetal development and in most human cancers, but is nearly absent in terminally differentiated normal tissues, making it an ideal target for selective therapy (Source: PMID: 18708357). The peptide–MHC (pMHC) complexes formed by these antigens are recognized by T-cell receptors (TCRs) on cytotoxic T-lymphocytes or by engineered TCR-like antibodies, triggering an immune-mediated attack on the tumor cells (Source: PMID: 24457417). Therapeutic strategies targeting these complexes include peptide vaccines like SurVaxM, TCR-engineered T-cell (TCR-T) therapies, and bispecific T-cell engagers designed to bypass traditional antigen processing (Source: clinicaltrials.gov).

Other names

MUC1-pMHCSurvivin-pMHCHLA-presented MUC1 and survivin peptidesBIRC5 peptide-MHCMUC1-HLA complexSurvivin-HLA complex

Induction of T-cell mediated cytotoxicity and immune recognition of tumor cells presenting specific MUC1 or survivin-derived peptides via T-cell receptor (TCR) or TCR-like antibody binding.